Nonspecific lymphocyte cytotoxicity in patients with malignant melanoma, renal cell carcinoma, and sarcomas, and in nontumor patients.
Mononuclear cell-mediated tumor cell destruction was studied in 114 patients with malignant melanoma, renal cell carcinoma, or sarcomas, and in 122 non-tumor-bearing control subjects, with the use of the microcytoxicity assay. Cytotoxic reactions were found in all patients and control groups against melanoma, renal carcinoma, sarcoma, and fibroblast-derived cell cultures; mean levels of cytotoxicity against allogeneic combinations of tumor cells and fibroblasts were similar in tumor-bearing and control patients. These results support the concept that the reactions found represent nonspecific cytotoxicity.
D000230:Adenocarcinoma / Q000276:immunology*; D000937:Antigen-Antibody Reactions; D000961:Antilymphocyte Serum; D003601:Cytotoxicity Tests, Immunologic; D005260:Female; D005347:Fibroblasts / Q000276:immunology; D006801:Humans; D008214:Lymphocytes / Q000276:immunology*; D008297:Male; D008545:Melanoma / Q000276:immunology*; D009368:Neoplasm Transplantation; D012509:Sarcoma / Q000276:immunology*; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum